Erik Foehr, Ph.D.

Summary:

• Bioanalytical expert with over 15 years of research and development experience, resulting in numerous publications, patents, and innovations that propel the advancement of science, medical treatment, and patient care.
• Strong scientific background, research capabilities, and business acumen that drive effective laboratory operations and project management.
• Experience with regulated bioanalysis of large and small molecules. Conducted development, validation and testing using chromatographic techniques (LC-MS/MS), ligand binding assays, neutralizing antibody activity assays, and immunogenicity assessment and testing.

Core Competencies:

• Leadership of bioanalysis research and drug development projects focused on increasing corporate brand, value proposition, and impact to the industry. Including contributions to IND, MHRA, and EMA submissions and interactions with regulators.
• Build infrastructure and manage bioanalytical sciences laboratory operations in compliance with good laboratory practices (GLP) and other regulatory guidelines.
• Drug Development competency as a member of senior leadership teams and steering committees, defining and executing plans to achieve overarching corporate goals.
• Diagnostic device development, validation and verification experience, including 510(k) application.
• Hire, train and lead high-performing, interdisciplinary teams of scientists, research associates, and lab operations personnel. Provide budget management, expense control and project management experience.
• Establish cooperative partnerships with academic medical centers and contract research organizations to collaborate on clinical trials and complex research studies.

Degrees & Certifications:

• Ph.D. in Physiology and Biophysics, UNIVERSITY OF CALIFORNIA, IRVINE, Irvine, CA
• Master of Science in Genetics, ARIZONA STATE UNIVERSITY, Tempe, AZ
• Bachelor of Science in Molecular Biology, UNIVERSITY OF CALIFORNIA, DAVIS, Davis, CA

\

Experience:

• Biomarin Pharmaceuticals Inc.- Director of bioanalytical laboratory developmental sciences department, including non-clinical and clinical research, regulatory compliance, and operations. Implement bioanalysis strategy in alignment with overarching corporate goals. Facilitate clinical and non-clinical studies, enabling the advancement of drug candidates to market.
• Diamics- Contributed to the launch of this entrepreneurial start-up company. Developed point-of-care cancer diagnostics using molecular and cell biology knowledge and biochemical techniques.
• AGY Therapeutics-Facilitated the design and execution of independent research programs focused on identifying, evaluating, validating, and characterizing target and off-target effects of drugs used to treat central nervous system disorders. Identified and evaluated drug candidates through pre-clinical phases of development leveraging nucleic acid analysis, protein biochemistry, cell biology, and analytical methods.
• J. David Gladstone, Institute of Virology and Immunology. Research Fellow investigating signal transduction pathways involved in neuro-inflammation. Created transgenic animal models to study learning and memory behavior and disease pathology.